Congress funds long-overdue research into a debilitating condition affecting millions of women
H.R. 8160 — Premenstrual Dysphoric Disorder Awareness and Research Act of 2026 · Filed by Yassamin Ansari (D-AZ) · 29 cosponsors · Introduced Mar 30, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the National Institutes of Health and the Department of Health and Human Services to expand research into Premenstrual Dysphoric Disorder (PMDD), a severe hormonal condition affecting 5–8% of women and people assigned female at birth. It funds public awareness campaigns, provider education, training grants for health professionals, and data collection on PMDD prevalence and barriers to care—aiming to reduce stigma and improve diagnosis and treatment access.
Why we flagged it
The bill is a straightforward public-health authorization statute that funds NIH research, provider education, and training programs for a historically under-researched medical condition. It contains no tax provisions, regulatory changes, or private-sector incentives—purely public investment in health infrastructure and knowledge.
What the text implies
- Expanded PMDD research and provider training may increase diagnosis rates, potentially shifting healthcare utilization patterns and increasing demand for mental-health and gynecological services.
- Public awareness campaigns may reduce stigma around menstrual-health conditions more broadly, with spillover effects on other reproductive-health discussions and care-seeking behavior.
The full analysis lists 3 implications of this text.
Who stands to gain
academic medical centers and nursing schools (grant recipients); hospitals and residency programs (training program funding); pharmaceutical companies developing PMDD treatments (indirectly, via expanded market awareness)